1-3 of 3
Thomas Blevins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes

Roy W. Beck, Carol J. Levy, Yogish C. Kudva, Keta Pandit, Thomas Blevins, Dan Raghinaru, Jordan E. Pinsker
Journal: Clinical Diabetes
Clin Diabetes 2024;42(4):547–549
https://doi.org/10.2337/cd23-0107
Published: 17 April 2024
View article titled, Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes
Open the PDF for Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes in another window
Journal Articles

Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes

Carol J. Levy, Dan Raghinaru, Yogish C. Kudva, Keta Pandit, Thomas Blevins, Luis Casaubon, Donna Desjardins, Camilla M. Levister, Grenye O’Malley, Corey Reid, John Lum, Craig Kollman, Roy W. Beck
Journal: Clinical Diabetes
Clin Diabetes 2024;42(1):116–124
https://doi.org/10.2337/cd23-0025
Published: 28 August 2023
View article titled, Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes
Open the PDF for Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes in another window
Journal Articles

Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes

Simon Heller, João Filipe Raposo, Santiago Tofé, Wasim Hanif, Zbynek Schroner, Su Down, Thomas Blevins
Journal: Clinical Diabetes
Clin Diabetes 2023;41(2):154–162
https://doi.org/10.2337/cd22-0016
Published: 09 August 2022
View article titled, Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
Open the PDF for Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes in another window